Uterine Corpus Cancer Subcommittee

Purpose

The NRG Oncology Uterine Corpus Cancer Subcommittee’s purpose is to improve the live of patients with uterine cancer by designing and conducting practice-changing multi-institutional clinical trials and translational research. This committee focuses on developing and testing innovative advanced surgical, radiation oncology, and systemic (including chemotherapy and other targeted/biologic therapies) technologies for patients with gynecologic uterine malignancies. Additionally, the committee is committed to identifying and rectifying disparities in patient outcomes within this population.

The goals of this committee include developing national and international priorities, goals, and initiatives for the management of uterine cancer; developing and managing currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of uterine corpus cancers; and, fostering the advancement of promising therapeutics in development and exploring potential translational research and biomarker development for incorporation into future clinical trials. This committee strives to develop and implement standardized procedures needed to design and conduct a research protocol within NRG while identifying potential barriers, and potential solutions to improve enrollment to NRG clinical trials in uterine corpus cancers, including fostering international collaboration. This committee meets four times a year, twice in-person and two virtual interim meetings.

Uterine Corpus Cancer Subcommittee Leadership

Chair

Matthew Powell, MD

Vice Chair

Ann Klopp, MD
Working Groups

Gestational Trophoblastic Working Group

Cf/ctDNA Working Group

Protocol 210 Working Group

Core Committee Members

Core Members

  • Mariam AlHilli
  • Therese Youssef Andraos
  • Floor Backes
  • Victoria Bae-Jump
  • Emma L. Barber
  • Joyce Barlin
  • Kelley Carrick
  • Bradley R. Corr
  • Casey Cosgrove
  • Kathleen Darcy
  • Linda Duska
  • Britt Erickson
  • Ramez Eskander
  • Ashley Felix
  • Idalid Franco
  • Katherine Fuh
  • Neil Horowitz
  • Anuja Jhingran
  • Namita Khanna
  • Sarah H. Kim
  • Lindsay M. Kuroki
  • Lisa M. Landrum
  • Helen J. Mackay
  • Vicky Makker
  • Cara Mathews
  • Colleen McCormick
  • David Miller
  • Amanda Nickels-Fader
  • Brian C. Orr
  • Bhavana Pothuri
  • Allison Puechl
  • Bobbie J. Rimel
  • Emma Rossi
  • Andrea Russo
  • Brian Slomovitz
  • Michael Toboni

General Members

  • Amy Armstong
  • Jamie Bakkum-Gamez
  • Emma Barber
  • David Bender
  • Leslie S. Bradford
  • Susana Campos
  • Michael E. Carney
  • Tara Castellano
  • David Cella
  • Aine Clements
  • Christopher H. Chapman
  • Joshua Cohen
  • Bradley Corr
  • Janell Darby
  • Amanda Nickles Fader
  • Julia Fehniger
  • Peter Frederick
  • Marina Frimer
  • Valerie Galvan-Turner
  • Sarah Gill
  • Allison Gockley
  • Gregory Gressel
  • Craig E. Grossman
  • Michael Guy
  • Kosei Hasegawa
  • James Hoffman
  • Elizabeth Hopp
  • Krisha Howell
  • Megan L. G. Hutchcraft
  • Elizabeth Jewell
  • Sokbom Kang
  • Juraj Kavecansky
  • Christi Kim
  • Christine Kim
  • Min Kyu Kim
  • Emily Ko
  • Katherine Kurnit
  • Olivia Lara
  • Nita Lee
  • Kimberly Leslie
  • Jennifer MacDonald
  • Larry Maxwell
  • Lindsey A. McAlarnen
  • Carolyn McCourt
  • Ida Micaily
  • Kathryn Mills
  • Jennifer Mueller
  • Carolyn Muller
  • David Mutch
  • Mario Javier Pineda
  • Lisa Rauh-Benoit
  • Bobbie Jo Rimel
  • Tyler Robin
  • Maria Rubinstein
  • Chelsea Salyer
  • Julian Schink
  • William Small
  • Jessica D. St. Laurent
  • Edward Tanner
  • Sarah Temkin
  • Neil K. Taunk
  • Akila Viswanathan
  • Tilley Jenkins Vogel
  • Boris Winterhoff
  • Aaron Wolfson
  • Catheryn Yashar

Patient Representatives

Dana Moore

QOL Representative

Elizabeth Jewell

Medical Oncology Representative

Martee Hensley

Reset all column filters
Study Title Status Phase Disease Category Disease Site
GOG-0184

A RANDOMIZED PHASE III STUDY OF TUMOR VOLUME DIRECTED PELVIC PLUS OR MINUS PARA-AORTIC IRRADIATION FOLLOWED BY CISPLATIN AND DOXORUBICIN OR CISPLATIN, DOXORUBICIN AND PACLITAXEL FOR ADVANCED ENDOMETRIAL CARCINOMA

 Terminated III Gynecologic [GY] Uterine Corpus
GOG-0238

A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

 Complete II Gynecologic [GY] Uterine Corpus
GOG-0277

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

 Terminated III Gynecologic [GY] Uterine Corpus
GOG-0286B

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

 Complete II/III Gynecologic [GY] Uterine Corpus
NRG-CC010

A Phase III Trial of the Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer

 Open to Accrual III Gynecologic [GY] Uterine Corpus
NRG-GY008

A Phase II Evaluation of Copanlisib (BAY 80-6946) (IND #130822), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations

 Complete II Gynecologic [GY] Uterine Corpus
NRG-GY011

A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus

 Terminated II Gynecologic [GY] Uterine Corpus
NRG-GY012

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer

 Closed to Accrual II Gynecologic [GY] Uterine Corpus
NRG-GY018

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

 Closed to Accrual & Treatment III Gynecologic [GY] Uterine Corpus
NRG-GY020

A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

 Closed to Accrual & Treatment III Gynecologic [GY] Uterine Corpus
NRG-GY025

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

 Open to Accrual II Gynecologic [GY] Uterine Corpus
NRG-GY026

A Phase III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

 Open to Accrual III Gynecologic [GY] Uterine Corpus
NRG-GY028

A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer

 Closed to Accrual I/II Gynecologic [GY] Uterine Corpus
NRG-GY031

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

 Open to Accrual I Gynecologic [GY] Uterine Corpus
NRG-GY032

A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)

 Open to Accrual II Gynecologic [GY] Uterine Corpus
NRG-GY035

A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

 Open to Accrual III Gynecologic [GY] Uterine Corpus
RTOG-1203

A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

 Terminated III Gynecologic [GY] Other

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.